Press releases

Specialist in pharmacology and preclinical studies in infectious diseases, Dr Bernard Scorneaux has led the studies of several drug...

Four directors of international standing and experts in pharmaceutical industry and antibiotics join the Board of Directors: Bernard Fanget...

DEINOVE (Alternext Paris: ALDEI), a biotech company that discovers, develops and produces high-value compounds from rare bacteria, notably...

Completion of the contribution in kind of DEINOBIOTICS’ shares to DEINOVE which now holds 100% of its subsidiary Consequential DEINOVE’s...

First patent applications coming out of DEINOBIOTICS’ research and pertaining to an innovative antibiotic structure Preparation underway to...

ADEME has validated key step 3 of the DEINOCHEM program after the performance targets were met for the production of the compounds of...

DEINOVE has entered into a significant collaboration with Processium, a company specialized in process design, for the production of...

Cash position: +€10.4 M at June 30, 2016 compared to +€12.4 M at December 31, 2015 Stability of interim net loss at -€3.1M Strategic...

ADEME has validated the 2nd key milestone of the DEINOCHEM program. Crossing this milestone was conditional on achieving deliverables...

The goal of this competition is to bring out the talents and future champions of the French economy through eight strategic goals set by...